Short answer
Aardvark Therapeutics, Inc. (AARD) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$22M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$22M
- −131.9% YoY
- EPS (diluted)
- −$0.99
- −39.4% YoY
Source: XBRL data from the Aardvark Therapeutics, Inc. (AARD) Q1 2026 10-Q on SEC EDGAR. USD.
Aardvark Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- ARD-101 enrollment and dosing paused in February 2026 after reversible cardiac observations in a healthy volunteer study
- Regulatory risk: FDA collaboration required to determine next steps for HERO and OLE trials, with guidance expected in Q2 2026
- Liquidity risk: $91.2 million in cash, equivalents and short-term investments projected to fund operations into mid-2027
- Financing risk: shelf registration permits equity or debt offerings up to $400.0 million
- Clinical-stage concentration: business success primarily dependent on ARD-101 development, approval and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aardvark Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.